ArticleBMC infectious diseases2025
Bioinformatics analysis of the proteome in the pathway of complement and coagulation cascades in COVID-19: discovering potential biomarkers of FGB and SERPINA5.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of Fibrinogen Beta Chain (FGB) rs1800790 and ITGB3 rs5918 gene variants with coagulation and ınflammation parameters according to sex in COVID-19 patients.Journal of thrombosis and thrombolysis · 2026Article
- Sex- and Age-Dependent Neuroimmune Dysregulation and Early Neurodegenerative Signatures Following SARS-CoV-2 Infection in Golden Syrian Hamsters.Research square · 2026Article
- Small extracellular vesicles proteome reveals persistent inflammatory and coagulopathic dysregulation in long-COVID.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The complement system, a key innate immunity component, is implicated in COVID-19 pathogenesis. Proteomic studies reveal dysregulated complement and coagulation cascades (CCC) proteins in COVID-19, yet comprehensive analyses remain limited. This bioinformatics study analyzed proteomic data (from inception to January 13, 2025) across Web of Science, PubMed, EMBASE, and Wiley Online Library using keywords "complement and coagulation cascades", "COVID-19", and "proteomics". Included studies compared differentially expressed proteins (DEPs) in COVID-19 patients versus healthy controls. Two reviewers independently extracted data. DEPs were analyzed via R (v4.4.2), Stata (v14), and STRING (v12.0). Twenty studies identified 3,018 DEPs, including 58 CCC-related genes (e.g., FGB, SERPINA5, FGG, F2). Hub genes were identified using MCODE and cytohubba in Cytoscape, and 16 hub genes (e.g., FGB, SERPINA5) were found. Stata confirmed consistent expression of FGB, SERPINA5, FGG, and F2. All of them are the biomarkers of diseases, and are the drug targets except SERPINA5 according to the reports from OpenTargets database. Immunohistochemistry validated FGB upregulation and SERPINA5 downregulation. In summary, CCC pathway proteins are extensively dysregulated in COVID-19. FGB and SERPINA5 are potential diagnostic biomarkers and therapeutic targets, offering insights into severe COVID-19 mechanisms and guiding novel treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.